Medication info
Linatin Plus Tablet 2.5/500 mg

Linatin Plus Tablet 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Bright yellow, oval-shaped, bi-convex film-coated tablet
Packaging
PTP - 10 tablets/PTP [x6 units]
Approval status
Active

MFDS item code 202203839 · Approved 2022.10.14 · Insurance code 645406260

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug treatment whose blood glucose is inadequately controlled with monotherapy, the initial dose of this drug is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3, Precautions for administration to the following patients, under Precautions for use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Do not administer to the following patients, under Precautions for use).

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication is used to help patients with type 2 diabetes control their blood sugar by taking linagliptin and metformin together. When taken alongside dietary and exercise therapy, this medication can help manage blood sugar more effectively. This can stabilize blood sugar levels and assist in improving health status.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug treatment whose blood glucose is inadequately controlled with monotherapy, the initial dose of this drug is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3, Precautions for administration to the following patients, under Precautions for use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Do not administer to the following patients, under Precautions for use).

Precautions

This medication helps in controlling blood sugar. However, it may cause a rare side effect called lactic acidosis, and should not be used in cases of impaired kidney function or issues with the heart or liver. Additionally, it should not be administered to patients with allergies to the main ingredients or other components, those with type 1 diabetes, acute infections, or severe dehydration. Hypoglycemic symptoms may occur during treatment, so especially when used in combination with sulfonylureas or insulin, blood sugar levels should be monitored carefully. In cases of impaired kidney function, this medication should be avoided or used with caution, and kidney function should be checked regularly through blood tests. If surgery is planned or radiocontrast iodine is administered, this medication should be stopped in advance, and restarted only after kidney function returns to normal following surgery or tests. Pregnant or breastfeeding women should avoid using this medication, and especially if planning to become pregnant, consult a physician to consider alternative treatment methods. Acute pancreatitis or skin blistering disorders may occur during treatment, so any abdominal pain or skin abnormalities should be reported to a doctor immediately. Additionally, this medication may lower vitamin B12 levels, so regular checking for vitamin B12 deficiency is necessary during prolonged use. It is not recommended for children and adolescents due to insufficient safety and efficacy, and elderly patients should carefully adjust their dosage considering declining kidney function. Lastly, this medication may interact with other medications, so inform your physician or pharmacist of any other medications being taken.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased vitamin B12 and deficiency
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 92 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • hearing loss
  • dizziness
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • hypertension
  • erectile dysfunction
  • goiter
  • anemia
  • vertigo
  • sensory loss
  • pruritus
  • insomnia
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyps
  • altered mental state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

Keep this medication in a tightly closed container to prevent exposure to air and moisture, and store it at room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Bright yellow, oval-shaped, bi-convex film-coated tablet

Package unit

PTP - 10 tablets/PTP [x6 units]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.